![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FREM1 |
Gene summary for FREM1 |
![]() |
Gene information | Species | Human | Gene symbol | FREM1 | Gene ID | 158326 |
Gene name | FRAS1 related extracellular matrix 1 | |
Gene Alias | BNAR | |
Cytomap | 9p22.3 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q5H8C1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
158326 | FREM1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.67e-02 | 3.29e-01 | -0.0811 |
158326 | FREM1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.26e-05 | 4.66e-01 | 0.0588 |
158326 | FREM1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.81e-35 | 8.34e-01 | 0.294 |
158326 | FREM1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.57e-09 | 1.78e+00 | 0.3487 |
158326 | FREM1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.40e-28 | 1.17e+00 | 0.281 |
158326 | FREM1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.13e-69 | 1.82e+00 | 0.3859 |
158326 | FREM1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.24e-04 | 2.42e-01 | 0.3005 |
158326 | FREM1 | A015-C-202 | Human | Colorectum | FAP | 3.41e-09 | 4.58e-01 | -0.0849 |
158326 | FREM1 | CRC-3-11773 | Human | Colorectum | CRC | 1.05e-06 | 3.67e-01 | 0.2564 |
158326 | FREM1 | S014 | Human | Liver | HCC | 1.30e-13 | 6.25e-01 | 0.2254 |
158326 | FREM1 | S015 | Human | Liver | HCC | 2.89e-12 | 7.01e-01 | 0.2375 |
158326 | FREM1 | S016 | Human | Liver | HCC | 2.50e-21 | 7.31e-01 | 0.2243 |
158326 | FREM1 | ATC13 | Human | Thyroid | ATC | 3.04e-38 | 8.24e-01 | 0.34 |
158326 | FREM1 | ATC5 | Human | Thyroid | ATC | 7.68e-49 | 8.77e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:00315892 | Colorectum | MSS | cell-substrate adhesion | 104/3467 | 363/18723 | 1.35e-06 | 4.51e-05 | 104 |
GO:00071602 | Colorectum | MSS | cell-matrix adhesion | 65/3467 | 233/18723 | 2.77e-04 | 3.67e-03 | 65 |
GO:00315893 | Colorectum | FAP | cell-substrate adhesion | 93/2622 | 363/18723 | 2.48e-09 | 4.61e-07 | 93 |
GO:00071603 | Colorectum | FAP | cell-matrix adhesion | 63/2622 | 233/18723 | 1.13e-07 | 7.43e-06 | 63 |
GO:00315894 | Colorectum | CRC | cell-substrate adhesion | 78/2078 | 363/18723 | 6.22e-09 | 1.49e-06 | 78 |
GO:00071604 | Colorectum | CRC | cell-matrix adhesion | 50/2078 | 233/18723 | 3.28e-06 | 1.47e-04 | 50 |
GO:0060348 | Colorectum | CRC | bone development | 37/2078 | 205/18723 | 1.96e-03 | 1.96e-02 | 37 |
GO:0048705 | Colorectum | CRC | skeletal system morphogenesis | 37/2078 | 220/18723 | 6.58e-03 | 4.71e-02 | 37 |
GO:003158922 | Liver | HCC | cell-substrate adhesion | 188/7958 | 363/18723 | 2.00e-04 | 1.55e-03 | 188 |
GO:000716021 | Liver | HCC | cell-matrix adhesion | 123/7958 | 233/18723 | 9.34e-04 | 5.47e-03 | 123 |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:006034813 | Thyroid | ATC | bone development | 102/6293 | 205/18723 | 1.18e-06 | 1.52e-05 | 102 |
GO:0060349 | Thyroid | ATC | bone morphogenesis | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
GO:00487053 | Thyroid | ATC | skeletal system morphogenesis | 101/6293 | 220/18723 | 9.48e-05 | 6.93e-04 | 101 |
GO:19048882 | Thyroid | ATC | cranial skeletal system development | 35/6293 | 68/18723 | 1.76e-03 | 8.71e-03 | 35 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FREM1 | SNV | Missense_Mutation | c.4553C>A | p.Ala1518Asp | p.A1518D | Q5H8C1 | protein_coding | tolerated(0.61) | benign(0.001) | TCGA-91-6829-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FREM1 | SNV | Missense_Mutation | c.6460N>T | p.Val2154Phe | p.V2154F | Q5H8C1 | protein_coding | deleterious(0.03) | probably_damaging(0.968) | TCGA-97-7554-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
FREM1 | SNV | Missense_Mutation | c.3083C>A | p.Ala1028Glu | p.A1028E | Q5H8C1 | protein_coding | tolerated(0.12) | benign(0.022) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD | |
FREM1 | SNV | Missense_Mutation | c.248A>T | p.His83Leu | p.H83L | Q5H8C1 | protein_coding | deleterious(0) | possibly_damaging(0.706) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD | |
FREM1 | SNV | Missense_Mutation | novel | c.1693C>T | p.Pro565Ser | p.P565S | Q5H8C1 | protein_coding | tolerated(0.08) | possibly_damaging(0.45) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FREM1 | SNV | Missense_Mutation | rs754692429 | c.5779C>A | p.Arg1927Ser | p.R1927S | Q5H8C1 | protein_coding | tolerated(0.74) | benign(0.003) | TCGA-NJ-A4YP-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FREM1 | SNV | Missense_Mutation | novel | c.4171N>A | p.Glu1391Lys | p.E1391K | Q5H8C1 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FREM1 | SNV | Missense_Mutation | c.154N>T | p.Pro52Ser | p.P52S | Q5H8C1 | protein_coding | tolerated(0.05) | benign(0.267) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
FREM1 | SNV | Missense_Mutation | novel | c.4136C>A | p.Pro1379His | p.P1379H | Q5H8C1 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FREM1 | SNV | Missense_Mutation | novel | c.4160N>A | p.Ile1387Asn | p.I1387N | Q5H8C1 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |